Eli Lilly (NYSE:LLY) Advances Alopecia Study Results Amid 4% Share Price Rise
Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
Eli Lilly And Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) said adolescent patients with severe alopecia areata (AA) ...
Incyte, Eli Lilly present results from Phase 3 BRAVE-AA-PEDS study
Late-breaking results from Eli Lilly and Company (LLY) and Incyte (INCY) found adolescent patients with severe alopecia areata, AA, treated ...
Healio2d
Baricitinib effective in adolescents with severe alopecia areata, phase 3 data show
Thirty-six weeks of once-daily, oral baricitinib was associated with greater hair regrowth on the scalp, eyebrows and ...
Investing Snacks3h
Eli Lilly’s Bold Moves Fuel Stock Surge and Expansion
Eli Lilly revealed major advancements in its alopecia and atopic dermatitis studies, likely driving its 3.77% stock rise. The ...
Healio1d
Bempikibart may incite hair regrowth after treatment cessation in severe alopecia areata
Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to ...
Managed Healthcare Executive2d
Medicaid Coverage of JAK Inhibitors for Alopecia is Limited | AAD 2025
Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...
pharmaphorum10d
Lilly's Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit
Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
pharmaphorum1d
FDA gives Lilly’s Olumiant breakthrough status for hair loss
Eli Lilly’s Olumiant is facing tough competition in its approved rheumatoid arthritis indication, but could take the lead in alopecia areata (AA), a common cause of hair loss. The FDA has ...